Jerini AG Reports Financial Results for Fiscal Year 2006
29 mars 2007 05h39 HE
|
Jerini AG
Highlights of 2006:
* EUR 66.6 million in cash and cash equivalents as of December 31,
2006
* Increase in revenues to EUR 13.1 million from EUR 9.6 million in
2005
* Anticipated...
Jerini Expands Collaboration With Baxter to Develop Non-Intraveneous Hemophilia Therapy
06 févr. 2007 03h54 HE
|
Jerini AG
BERLIN, Feb. 6, 2007 (PRIME NEWSWIRE) -- Jerini AG announced today the expansion of their current research collaboration with Baxter AG for the development of a non-intravenous therapy for the...
Jerini Reports Financial Results for First Nine Months
14 nov. 2006 02h59 HE
|
Jerini AG
BERLIN, Nov. 14, 2006 (PRIMEZONE) -- Jerini AG (FSE:JI4) reported financial results according to International Financial Reporting Standards (IFRS) for the first nine months ended September 30,...
Jerini to Hold Press Conference at the European Academy of Dermatology and Venereology Congress in Rhodes, Greece
05 oct. 2006 08h56 HE
|
Jerini AG
BERLIN, Oct. 5, 2006 (PRIMEZONE) -- Jerini AG (FSE:JI4) announced today that Dr. Jochen Knolle, Chief Scientific Officer and Head of R&D at Jerini, and Dr. Adi Hoess, Chief Commercial Officer at...
Jerini Hosts Conference Call on Phase III Clinical Trials of Icatibant for Hereditary Angioedema
21 sept. 2006 19h49 HE
|
Jerini AG
BERLIN, Sept. 21, 2006 (PRIMEZONE) -- Jerini AG (FSE:JI4) will host an audio webcast and conference call, including an open question and answer session, on Friday, September 22nd, 2006, to discuss...
Jerini Announces Positive Results from Two Phase III Trials of Icatibant for the Treatment of Hereditary Angioedema
21 sept. 2006 16h50 HE
|
Jerini AG
BERLIN, Sept. 21, 2006 (PRIMEZONE) -- Jerini AG (FSE:JI4) announced today the results of its two pivotal Phase III trials (FAST-1 and FAST-2) for the subcutaneous treatment of hereditary angioedema...
Jerini Announces the Election of Two New Supervisory Board Members
03 juil. 2006 07h11 HE
|
Jerini AG
BERLIN, July 3, 2006 (PRIMEZONE) -- Jerini AG (FSE:JI4) announced today the appointments of Zsolt Lavotha and Dr. Gunter Stock to Jerini's Supervisory Board, as elected at the company's June 30th...
Jerini Completes Randomization of Last Patient in Phase III European Clinical Trial (FAST-2) of Icatibant for the Treatment of Hereditary Angioedema
07 juin 2006 03h09 HE
|
Jerini AG
-- Randomization now complete in both Phase III HAE trials
-- A total of 130 patients randomized in FAST-1 and FAST-2 trials
-- On track to report top line data in 3Q
-- Filing of US and...
Jerini AG Reports First Quarter Financial Results
15 mai 2006 04h50 HE
|
Jerini AG
BERLIN, May 15, 2006 (PRIMEZONE) -- Jerini AG (FSE:JI4) reported financial results for its first quarter ended March 31, 2006. Under International Financial Reporting Standards (IFRS), revenues for...
Jerini Appoints Andrew D. Curtis as Vice President U.S. Marketing for Jerini U.S., Inc.
02 mai 2006 05h21 HE
|
Jerini AG
BERLIN, May 2, 2006 (PRIMEZONE) -- Jerini AG (FSE:JI4) announced the appointment of Andrew D. Curtis as Vice President U.S. Marketing, effective May 1, 2006. Curtis will be heading Jerini's recently...